Literature DB >> 7632812

Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange.

A Pereira1, R Mazzara, J Monteagudo, C Sanz, L Puig, A Martínez, A Ordinas, R Castillo.   

Abstract

The aim of this study was to investigate pretreatment prognostic factors that could be useful in predicting the response to plasma exchange in thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS). Thirty-two patients with TTP/HUS, treated with plasma exchange at our institution from 1980 to 1994, were studied. The main clinical and laboratory data at the beginning of plasma exchanges were analyzed by the Cox stepwise logistic regression, applied to either treatment failure or death. Seventeen (53%) patients attained a complete remission and 22 (69%) survived (five in advanced renal failure and long-term hemodialysis). Longer delay in initiating plasma exchanges, presence of stupor or coma, and higher creatinine levels at the beginning of plasma exchanges were independent predictors of treatment failure. Stupor or coma at the beginning of plasma exchanges was the only predictor of mortality from unremitted TTP/HUS. Hemoglobin levels, platelet count, and LDH activity, traditionally envisaged as markers of disease activity, neither correlated with previous duration of TTP/HUS nor had any prognostic value. Early diagnosis of TTP/HUS and prompt initiation of intensive plasma exchange emerged from this study as the most effective interventions for improving the prognosis of TTP/HUS patients.

Entities:  

Mesh:

Year:  1995        PMID: 7632812     DOI: 10.1007/bf01696619

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  23 in total

Review 1.  Prostacyclin in thrombotic microangiopathy.

Authors:  G Remuzzi; C Zoja; E C Rossi
Journal:  Semin Hematol       Date:  1987-04       Impact factor: 3.851

Review 2.  HUS and TTP: variable expression of a single entity.

Authors:  G Remuzzi
Journal:  Kidney Int       Date:  1987-08       Impact factor: 10.612

Review 3.  Role of fibrinolysis in thrombotic thrombocytopenic purpura.

Authors:  H C Kwaan
Journal:  Semin Hematol       Date:  1987-04       Impact factor: 3.851

4.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

5.  Use of vincristine in refractory thrombotic thrombocytopenic purpura.

Authors:  M Levin; H W Grünwald
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

6.  Effect of splenectomy on von Willebrand factor multimeric structure in thrombotic thrombocytopenic purpura refractory to plasma exchange.

Authors:  A Pereira; J Monteagudo; A Bono; A Lopez-Guillermo; A Ordinas
Journal:  Blood Coagul Fibrinolysis       Date:  1993-10       Impact factor: 1.276

7.  Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura.

Authors:  J J Byrnes; J L Moake; P Klug; P Periman
Journal:  Am J Hematol       Date:  1990-07       Impact factor: 10.047

8.  Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group.

Authors:  G Rock; K Shumak; J Kelton; V S Blanchette; N Buskard; R Nair; R Spasoff
Journal:  Transfusion       Date:  1992-10       Impact factor: 3.157

9.  Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  J L Moake; P D McPherson
Journal:  Am J Med       Date:  1989-09       Impact factor: 4.965

10.  [Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study].

Authors:  P Henon
Journal:  Presse Med       Date:  1991-11-09       Impact factor: 1.228

View more
  14 in total

1.  Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome.

Authors:  Domenica Caramazza; Gerlando Quintini; Ignazio Abbene; Lucio Lo Coco; Alessandra Malato; Rosa Di Trapani; Giorgia Saccullo; Giuseppina Pizzo; Roberto Palazzolo; Rita Barone; Giuseppina Mazzola; Sergio Rizzo; Paolo Ragonese; Paolo Aridon; Vincenzo Abbadessa; Sergio Siragusa
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

2.  National questionnaire survey of TMA.

Authors:  Naomi Ito; Hideo Wada; Masanori Matsumoto; Yoshihiro Fujimura; Mitsuru Murata; Takashi Izuno; Minoru Sugita; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2009-09-18       Impact factor: 2.490

3.  A second national questionnaire survey of TMA.

Authors:  Naomi Ito-Habe; Hideo Wada; Masanori Matsumoto; Yoshihiro Fujimura; Mitsuru Murata; Takashi Izuno; Minoru Sugita; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2010-06-05       Impact factor: 2.490

4.  Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan.

Authors:  Masanori Matsumoto; Yoshihiro Fujimura; Hideo Wada; Koichi Kokame; Yoshitaka Miyakawa; Yasunori Ueda; Satoshi Higasa; Takanori Moriki; Hideo Yagi; Toshiyuki Miyata; Mitsuru Murata
Journal:  Int J Hematol       Date:  2017-05-26       Impact factor: 2.490

Review 5.  Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach.

Authors:  Sanjeev Baweja; Kate Wiggins; Darren Lee; Susan Blair; Margaret Fraenkel; Lawrence P McMahon
Journal:  J Artif Organs       Date:  2010-12-10       Impact factor: 1.731

6.  Outcome of severe adult thrombotic microangiopathies in the intensive care unit.

Authors:  Frédéric Pene; Cécile Vigneau; Marc Auburtin; Delphine Moreau; Jean-Ralph Zahar; Joël Coste; Farhad Heshmati; Jean-Paul Mira
Journal:  Intensive Care Med       Date:  2004-12-03       Impact factor: 17.440

7.  Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2.

Authors:  A Donohue-Rolfe; I Kondova; J Mukherjee; K Chios; D Hutto; S Tzipori
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

8.  Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.

Authors:  Ygal Benhamou; Cyrielle Assié; Pierre-Yves Boelle; Marc Buffet; Rana Grillberger; Sandrine Malot; Alain Wynckel; Claire Presne; Gabriel Choukroun; Pascale Poullin; François Provôt; Didier Gruson; Mohamed Hamidou; Dominique Bordessoule; Jacques Pourrat; Jean-Paul Mira; Véronique Le Guern; Claire Pouteil-Noble; Cédric Daubin; Philippe Vanhille; Eric Rondeau; Jean-Bernard Palcoux; Christiane Mousson; Cécile Vigneau; Guy Bonmarchand; Bertrand Guidet; Lionel Galicier; Elie Azoulay; Hanspeter Rottensteiner; Agnès Veyradier; Paul Coppo
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

Review 9.  The thrombocytopenic purpuras. Recognition and management.

Authors:  S Gillis
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

Review 10.  Management of thrombotic thrombocytopenic purpura: current perspectives.

Authors:  Piers Blombery; Marie Scully
Journal:  J Blood Med       Date:  2014-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.